Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serial Plasma Genotyping to Guide Adaptive Treatment of Advanced NSCLC Receiving First-line Pembrolizumab
NCT04166487Phase 2Active, not recruiting
- Start
- Jan 2020
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC). Started Jan 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04166487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166487.